37926-75-3

Basic information

• Product Name: (9xi,11beta,16beta)-9-fluoro-11,17-dihydroxy-16-methyl-3-oxoandrosta-1,4-diene-17-carboxylic acid
• Synonyms: Betamethasone 17-acid;Betametasone Impurity 1;Betamethasone Impurity 15;Betamethasone 17-Carboxylic Acid;Betamethasone sodium phosphate impurity F;Betamethasone Impurity 3 (Betamethasone 17-Carboxylic Acid);(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthrene-17-carboxylic acid;Betamethasone impurity 3/Betamethasone Acid/Betamethasone 17-Carboxylic Acid/(8S,9R,10S,11S,13S,14S,16S,17R)-9-Fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthrene-17-carboxylic acid
• CAS NO: 37926-75-3
• Molecular Formula: C₂₁H₂₇FO₅
• Molecular Weight: 378.4345
• Mol File: 37926-75-3.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 566.9°C at 760 mmHg
• Flash Point: 296.6°C
• Density: 1.35g/cm³
• Vapor Pressure: 3.28E-15mmHg at 25°C
• Refractive Index: 1.598
• CAS DataBase Reference: (9xi,11beta,16beta)-9-fluoro-11,17-dihydroxy-16-methyl-3-oxoandrosta-1,4-diene-17-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (9xi,11beta,16beta)-9-fluoro-11,17-dihydroxy-16-methyl-3-oxoandrosta-1,4-diene-17-carboxylic acid(37926-75-3)
• EPA Substance Registry System: (9xi,11beta,16beta)-9-fluoro-11,17-dihydroxy-16-methyl-3-oxoandrosta-1,4-diene-17-carboxylic acid(37926-75-3)

Safety Data

• Hazardous Substances Data: 37926-75-3(Hazardous Substances Data)

Usage

General Description

"(9xi,11beta,16beta)-9-fluoro-11,17-dihydroxy-16-methyl-3-oxoandrosta-1,4-diene-17-carboxylic acid" is a synthetic steroid chemical compound. It is a fluoro derivative of the hormone cortisol, which is produced by the adrenal glands in the human body. (9xi,11beta,16beta)-9-fluoro-11,17-dihydroxy-16-methyl-3-oxoandrosta-1,4-diene-17-carboxylic acid has anti-inflammatory and immune-suppressing properties, making it useful in the treatment of various inflammatory and autoimmune conditions. The presence of a fluorine atom in the compound enhances its potency and duration of action, making it more effective than natural cortisol. However, like other steroids, it may also have potential side effects, such as suppression of the immune system and metabolic disturbances. Overall, "(9xi,11beta,16beta)-9-fluoro-11,17-dihydroxy-16-methyl-3-oxoandrosta-1,4-diene-17-carboxylic acid" is a powerful synthetic steroid with therapeutic potential but must be used with caution.

Upstream product

• 378-44-9 betamethasone 

Downstream Products

• 79578-14-6 17α-acetoxy-9α-fluoro-11β-hydroxy-17β-<(methylthio)carbonyl>-16β-methylandrosta-1,4-dien-3-one 
• 87116-72-1 11β,17α-dihydroxy-9α-fluoro-17β-<(methylthio)carbonyl>-16β-methylandrosta-1,4-dien-3-one 

Relevant articles and documents

GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF

Provided herein are glucocorticoid receptor agonist immunoconjugates, glucocorticoid receptor agonists, pharmaceutical compositiosn including the same, and methods of using the same.

Mechanism of base-catalyzed autooxidation of corticosteroids containing 20-keto-21-hydroxyl side chain

Corticosteroids and related compounds containing the 20-keto-21-hydroxyl side chain such as betamethasone, betamethasone 9,11-epoxide, dexamethasone, and dexamethasone 9,11-epoxide have been found to undergo facile autooxidation on the 1,3-dihydroxyaceton

Novel androstane-17β-carboxylic acid esters

The invention refers to compounds having anti-inflammatory activity characterized by the formula STR1 or a stereoisomeric component thereof, in which formula X1 represents a hydrogen, chlorine, bromine or fluorine atom; X2 represents a hydrogen, chlorine, bromine or fluorine atom; R1 represents a β-hydroxy group, a β-chlorine atom or an oxo group; R2 represents a hydrogen atom, a methylene group or an α- or β-methyl group; R3 represents a hydrogen atom or an acyl group of 1 through 8 carbon atoms; R4 represents a hydrogen atom, a (C1 -C5) alkyl group or a phenyl group; R5 represents a hydrogen atom, a (C1 -C5) alkyl group or a phenyl group; Y represents either CR7 R8, O, S or NR9, where R7, R8 and R9 are selected from hydrogen or from straight or branched hydrocarbon chains having 1-8 carbon atoms or from a phenyl group. R6 represents a hydrogen; a methyl group; a phenyl or an alkenyl or cycloalkylene group optionally substituted by alkyl, nitro, carboxy, alkoxy, halogen, cyano, carbalkoxy and trifluoromethyl group(s); a (C1 -C5) alkyl group substituted by at least one halogen atom; a saturated or unsaturated carbocyclic or heterocyclic (O, S, N) ring system containing 3-10 atoms in the ring system; a C1 alkyl group substituted by either one or two alicyclic or aromatic 3,4,5 or 6-numbered ring system(s) or one, two or three straight or branched alkyl or alkenyl group(s) of 1 through 18 carbon atoms; and represents a single or double bond. The invention also refers to a process and intermediates for the preparation of these compounds, a pharmaceutical preparation containing one of the compounds and a method for the treatment of inflammatory conditions.